India · Delayed Price · Currency is INR Biocon Statistics
Total Valuation
Biocon has a market cap or net worth of INR 604.02 billion. The enterprise value is 757.26 billion.
| Market Cap | 604.02B |
| Enterprise Value | 757.26B |
Important Dates
The last earnings date was Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Jul 3, 2026 |
Share Statistics
Biocon has 1.63 billion shares outstanding. The number of shares has increased by 23.57% in one year.
| Current Share Class | 1.63B |
| Shares Outstanding | 1.63B |
| Shares Change (YoY) | +23.57% |
| Shares Change (QoQ) | +1.86% |
| Owned by Insiders (%) | 44.71% |
| Owned by Institutions (%) | 27.82% |
| Float | 826.97M |
Valuation Ratios
The trailing PE ratio is 126.18 and the forward PE ratio is 68.19. Biocon's PEG ratio is 1.33.
| PE Ratio | 126.18 |
| Forward PE | 68.19 |
| PS Ratio | 3.47 |
| PB Ratio | 1.63 |
| P/TBV Ratio | 11.06 |
| P/FCF Ratio | 180.46 |
| P/OCF Ratio | 30.82 |
| PEG Ratio | 1.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.60, with an EV/FCF ratio of 226.25.
| EV / Earnings | 167.50 |
| EV / Sales | 4.35 |
| EV / EBITDA | 20.60 |
| EV / EBIT | 47.70 |
| EV / FCF | 226.25 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.22 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 4.27 |
| Debt / FCF | 46.90 |
| Interest Coverage | 1.83 |
Financial Efficiency
Return on equity (ROE) is 0.97% and return on invested capital (ROIC) is 3.04%.
| Return on Equity (ROE) | 0.97% |
| Return on Assets (ROA) | 1.55% |
| Return on Invested Capital (ROIC) | 3.04% |
| Return on Capital Employed (ROCE) | 3.14% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | 10.59M |
| Profits Per Employee | 274,883 |
| Employee Count | 16,447 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.04 |
Taxes
In the past 12 months, Biocon has paid 218.00 million in taxes.
| Income Tax | 218.00M |
| Effective Tax Rate | 6.02% |
Stock Price Statistics
The stock price has decreased by -3.67% in the last 52 weeks. The beta is 0.34, so Biocon's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -3.67% |
| 50-Day Moving Average | 367.24 |
| 200-Day Moving Average | 390.10 |
| Relative Strength Index (RSI) | 60.03 |
| Average Volume (20 Days) | 3,310,260 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocon had revenue of INR 174.15 billion and earned 4.52 billion in profits. Earnings per share was 2.94.
| Revenue | 174.15B |
| Gross Profit | 107.17B |
| Operating Income | 15.88B |
| Pretax Income | 3.62B |
| Net Income | 4.52B |
| EBITDA | 36.07B |
| EBIT | 15.88B |
| Earnings Per Share (EPS) | 2.94 |
Balance Sheet
The company has 26.87 billion in cash and 156.98 billion in debt, with a net cash position of -130.11 billion or -79.91 per share.
| Cash & Cash Equivalents | 26.87B |
| Total Debt | 156.98B |
| Net Cash | -130.11B |
| Net Cash Per Share | -79.91 |
| Equity (Book Value) | 371.56B |
| Book Value Per Share | 210.91 |
| Working Capital | 32.79B |
Cash Flow
In the last 12 months, operating cash flow was 19.60 billion and capital expenditures -16.25 billion, giving a free cash flow of 3.35 billion.
| Operating Cash Flow | 19.60B |
| Capital Expenditures | -16.25B |
| Depreciation & Amortization | 20.20B |
| Net Borrowing | -21.38B |
| Free Cash Flow | 3.35B |
| FCF Per Share | 2.06 |
Margins
Gross margin is 61.54%, with operating and profit margins of 9.12% and 2.60%.
| Gross Margin | 61.54% |
| Operating Margin | 9.12% |
| Pretax Margin | 2.08% |
| Profit Margin | 2.60% |
| EBITDA Margin | 20.71% |
| EBIT Margin | 9.12% |
| FCF Margin | 1.92% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.13%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.13% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.07% |
| FCF Payout Ratio | 24.32% |
| Buyback Yield | -23.57% |
| Shareholder Yield | -23.43% |
| Earnings Yield | 0.79% |
| FCF Yield | 0.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Biocon is 411.84, which is 11.02% higher than the current price. The consensus rating is "Buy".
| Price Target | 411.84 |
| Price Target Difference | 11.02% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 12.88% |
| EPS Growth Forecast (3Y) | 35.23% |
Stock Splits
The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jun 12, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |